PMID- 11138734
OWN - NLM
STAT- MEDLINE
DCOM- 20010301
LR  - 20190725
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 84
IP  - 3
DP  - 2000 Nov
TI  - Correlation between adenine nucleotide-induced cyclic AMP elevation and 
      extracellular adenosine formation in NG108-15 cells.
PG  - 325-33
AB  - We previously demonstrated that extracellular adenine nucleotides induced cyclic 
      AMP elevation in NG108-15 cells. This response was resistant to adenosine 
      deaminase (ADA) and the ecto-5'-nucleotidase (CD73) inhibitor 
      alpha,beta-methylene ADP (alpha,beta-MeADP), but was inhibited by both P1- and 
      P2-receptor antagonists. In the present study, we investigated the relationship 
      between adenine nucleotide-induced cyclic AMP elevation and extracellular 
      adenosine formation. ATP, AMP and beta,gamma-methylene ATP (beta,gamma-MeATP) 
      were time-dependently metabolized to adenosine in NG108-15 cells. Adenosine 
      formations from ATP, AMP and beta,gamma-MeATP were not affected by 
      alpha,beta-MeADP, but suppressed by the P2-receptor antagonist 
      pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS). A close 
      correlation between extracellular adenosine formation and cyclic AMP increasing 
      effects were obtained with several adenine nucleotide agonists in NG108-15 cells 
      as well as their parent cell line C6Bu-1 and N18TG-2 cells, all of which possess 
      functional adenosine A2 receptors. When NG108-15 cells were incubated with 
      [3H]ATP or [3H]AMP in the presence of ADA, [3H]adenosine was found to distribute 
      dominantly on the cell surface. NG108-15 cells expressed mRNA for the ecto-ATPase 
      and nucleotide pyrophosphatase, but not for CD73. These results suggest that 
      local adenosine formation by an ecto-enzyme distinct from CD73 is involved in 
      adenine nucleotide-induced cyclic AMP formation in NG108-15 cells.
FAU - Ohkubo, S
AU  - Ohkubo S
AD  - Department of Cellular Signaling, Graduate School of Pharmaceutical Sciences, 
      Tohoku University, Sendai, Japan.
FAU - Kimura, J
AU  - Kimura J
FAU - Matsuoka, I
AU  - Matsuoka I
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 0 (Adenine Nucleotides)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - 0 (RNA, Messenger)
RN  - 0T2A5439OE (alpha,beta-methyleneadenosine 5'-diphosphate)
RN  - 149017-66-3 (pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - 5V5IOJ8338 (Pyridoxal Phosphate)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - E0399OZS9N (Cyclic AMP)
RN  - EC 3.1.3.- (Nucleotidases)
RN  - EC 3.1.3.31 (nucleotidase)
RN  - K72T3FS567 (Adenosine)
SB  - IM
MH  - Adenine Nucleotides/*metabolism
MH  - Adenosine/*biosynthesis
MH  - Adenosine Diphosphate/*analogs & derivatives/pharmacology
MH  - Adenosine Monophosphate/metabolism/pharmacology
MH  - Adenosine Triphosphate/metabolism
MH  - Animals
MH  - Cell Membrane/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Cyclic AMP/*metabolism
MH  - Enzyme Inhibitors/pharmacology
MH  - Extracellular Space/metabolism
MH  - Nucleotidases/antagonists & inhibitors/metabolism
MH  - Purinergic P2 Receptor Antagonists
MH  - Pyridoxal Phosphate/*analogs & derivatives/pharmacology
MH  - RNA, Messenger/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Cells, Cultured
EDAT- 2001/01/04 11:00
MHDA- 2001/03/07 10:01
CRDT- 2001/01/04 11:00
PHST- 2001/01/04 11:00 [pubmed]
PHST- 2001/03/07 10:01 [medline]
PHST- 2001/01/04 11:00 [entrez]
AID - 10.1254/jjp.84.325 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 2000 Nov;84(3):325-33. doi: 10.1254/jjp.84.325.